vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与世纪互联（VNET）财务数据对比。点击上方公司名可切换其他公司
BIOCRYST PHARMACEUTICALS INC的季度营收约是世纪互联的1.1倍（$406.6M vs $362.7M），BIOCRYST PHARMACEUTICALS INC净利率更高（60.5% vs -10.7%，领先71.1%），BIOCRYST PHARMACEUTICALS INC自由现金流更多（$291.2M vs $-193.1M），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（109.4% vs 17.4%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
VNET Group即世纪互联，是中国领先的第三方中立数据中心服务商，提供机柜托管、云基础设施、混合云部署及网络管理等解决方案，服务覆盖科技、金融、零售等多领域企业客户，为企业数字化运营提供稳定的算力与网络支撑。
BCRX vs VNET — 直观对比
营收规模更大
BCRX
是对方的1.1倍
$362.7M
净利率更高
BCRX
高出71.1%
-10.7%
自由现金流更多
BCRX
多$484.2M
$-193.1M
两年增速更快
BCRX
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $406.6M | $362.7M |
| 净利润 | $245.8M | $-38.7M |
| 毛利率 | 97.7% | 20.9% |
| 营业利润率 | 64.0% | 0.5% |
| 净利率 | 60.5% | -10.7% |
| 营收同比 | 209.1% | — |
| 净利润同比 | 1017.5% | — |
| 每股收益（稀释后） | $1.13 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCRXVNET
| Q4 25 | $406.6M | — | ||
| Q3 25 | $159.4M | $362.7M | ||
| Q2 25 | $163.4M | — | ||
| Q1 25 | $145.5M | $309.5M | ||
| Q4 24 | $131.5M | — | ||
| Q3 24 | $117.1M | $302.2M | ||
| Q2 24 | $109.3M | $274.4M | ||
| Q1 24 | $92.8M | $262.9M |
净利润BCRXVNET
| Q4 25 | $245.8M | — | ||
| Q3 25 | $12.9M | $-38.7M | ||
| Q2 25 | $5.1M | — | ||
| Q1 25 | $32.0K | $-2.4M | ||
| Q4 24 | $-26.8M | — | ||
| Q3 24 | $-14.0M | $-2.1M | ||
| Q2 24 | $-12.7M | $-1.1M | ||
| Q1 24 | $-35.4M | $-22.0M |
毛利率BCRXVNET
| Q4 25 | 97.7% | — | ||
| Q3 25 | 98.6% | 20.9% | ||
| Q2 25 | 98.3% | — | ||
| Q1 25 | 96.9% | 25.2% | ||
| Q4 24 | 95.4% | — | ||
| Q3 24 | 97.3% | 23.2% | ||
| Q2 24 | 98.4% | 21.3% | ||
| Q1 24 | 98.6% | 21.6% |
营业利润率BCRXVNET
| Q4 25 | 64.0% | — | ||
| Q3 25 | 18.6% | 0.5% | ||
| Q2 25 | 18.2% | — | ||
| Q1 25 | 14.6% | 0.1% | ||
| Q4 24 | -3.4% | — | ||
| Q3 24 | 6.6% | 24.5% | ||
| Q2 24 | 8.0% | 0.2% | ||
| Q1 24 | -15.6% | 0.2% |
净利率BCRXVNET
| Q4 25 | 60.5% | — | ||
| Q3 25 | 8.1% | -10.7% | ||
| Q2 25 | 3.1% | — | ||
| Q1 25 | 0.0% | -0.8% | ||
| Q4 24 | -20.4% | — | ||
| Q3 24 | -12.0% | -0.7% | ||
| Q2 24 | -11.6% | -0.4% | ||
| Q1 24 | -38.1% | -8.4% |
每股收益（稀释后）BCRXVNET
| Q4 25 | $1.13 | — | ||
| Q3 25 | $0.06 | — | ||
| Q2 25 | $0.02 | — | ||
| Q1 25 | $0.00 | — | ||
| Q4 24 | $-0.13 | — | ||
| Q3 24 | $-0.07 | — | ||
| Q2 24 | $-0.06 | — | ||
| Q1 24 | $-0.17 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $274.7M | $492.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-119.2M | $890.8M |
| 总资产 | $514.2M | $6.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCRXVNET
| Q4 25 | $274.7M | — | ||
| Q3 25 | $212.9M | $492.1M | ||
| Q2 25 | $260.0M | — | ||
| Q1 25 | $295.1M | $544.3M | ||
| Q4 24 | $320.9M | — | ||
| Q3 24 | $96.8M | $219.5M | ||
| Q2 24 | $78.4M | $247.2M | ||
| Q1 24 | $84.3M | $246.9M |
总债务BCRXVNET
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BCRXVNET
| Q4 25 | $-119.2M | — | ||
| Q3 25 | $-387.9M | $890.8M | ||
| Q2 25 | $-421.6M | — | ||
| Q1 25 | $-451.9M | $927.8M | ||
| Q4 24 | $-475.9M | — | ||
| Q3 24 | $-468.6M | $902.9M | ||
| Q2 24 | $-475.6M | $900.6M | ||
| Q1 24 | $-476.2M | $895.1M |
总资产BCRXVNET
| Q4 25 | $514.2M | — | ||
| Q3 25 | $446.4M | $6.1B | ||
| Q2 25 | $457.2M | — | ||
| Q1 25 | $480.0M | $5.4B | ||
| Q4 24 | $490.4M | — | ||
| Q3 24 | $491.3M | $4.3B | ||
| Q2 24 | $472.4M | $4.0B | ||
| Q1 24 | $467.9M | $3.9B |
负债/权益比BCRXVNET
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.28× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $292.0M | $113.8M |
| 自由现金流经营现金流 - 资本支出 | $291.2M | $-193.1M |
| 自由现金流率自由现金流/营收 | 71.6% | -53.2% |
| 资本支出强度资本支出/营收 | 0.2% | 84.6% |
| 现金转化率经营现金流/净利润 | 1.19× | — |
| 过去12个月自由现金流最近4个季度 | $344.9M | $-589.7M |
8季度趋势，按日历期对齐
经营现金流BCRXVNET
| Q4 25 | $292.0M | — | ||
| Q3 25 | $41.6M | $113.8M | ||
| Q2 25 | $41.3M | — | ||
| Q1 25 | $-27.5M | $27.0M | ||
| Q4 24 | $-5.2M | — | ||
| Q3 24 | $8.2M | $108.3M | ||
| Q2 24 | $-1.4M | $55.8M | ||
| Q1 24 | $-53.7M | $37.1M |
自由现金流BCRXVNET
| Q4 25 | $291.2M | — | ||
| Q3 25 | $40.3M | $-193.1M | ||
| Q2 25 | $41.1M | — | ||
| Q1 25 | $-27.7M | $-220.0M | ||
| Q4 24 | $-5.9M | — | ||
| Q3 24 | $8.2M | $-95.0M | ||
| Q2 24 | $-1.5M | $-81.6M | ||
| Q1 24 | $-53.9M | $-102.2M |
自由现金流率BCRXVNET
| Q4 25 | 71.6% | — | ||
| Q3 25 | 25.3% | -53.2% | ||
| Q2 25 | 25.2% | — | ||
| Q1 25 | -19.0% | -71.1% | ||
| Q4 24 | -4.5% | — | ||
| Q3 24 | 7.0% | -31.4% | ||
| Q2 24 | -1.4% | -29.8% | ||
| Q1 24 | -58.1% | -38.9% |
资本支出强度BCRXVNET
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.8% | 84.6% | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.1% | 79.8% | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.1% | 67.3% | ||
| Q2 24 | 0.1% | 50.1% | ||
| Q1 24 | 0.3% | 53.0% |
现金转化率BCRXVNET
| Q4 25 | 1.19× | — | ||
| Q3 25 | 3.23× | — | ||
| Q2 25 | 8.12× | — | ||
| Q1 25 | -859.91× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
